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Abstract
Enumeration of anti-viral CD8+ T cells to make comparisons between mice, viruses and vaccines is a frequently used
approach, but controversy persists as to the most appropriate methods. Use of peptide-MHC tetramers (or variants) and
intracellular staining for cytokines, in particular IFNc, after a short ex vivo stimulation are now common, as are a variety of
cytotoxicity assays, but few direct comparisons have been made. It has been argued that use of tetramers leads to the
counting of non-functional T cells and that measurement of single cytokines will fail to identify cells with alternative
functions. Further, the linear range of these methods has not been tested and this is required to give confidence that
relative quantifications can be compared across samples. Here we show for two acute virus infections and CD8+ T cells
activated in vitro that DimerX (a tetramer variant) and intracellular staining for IFNc, alone or in combination with CD107 to
detect degranulation, gave comparable results at the peak of the response. Importantly, these methods were highly linear
over nearly two orders of magnitude. In contrast, in vitro and in vivo assays for cytotoxicity were not linear, suffering from
high background killing, plateaus in maximal killing and substantial underestimation of differences in magnitude of
responses.
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Introduction
CD8+ T cells play a crucial role in anti-viral immunity [1,2].
Their main functions are the elimination of infected cells by
cytotoxicity and production of a range of cytokines after activation
through their T cell receptor [3,4]. Accurate methods to quantify
CD8+ T cells are fundamental tools in viral immunology. The
earliest method to measure CD8+ T cell effector activity was the
chromium (51Cr) release assay which indirectly measures the
viability of 51Cr-labeled target cells after incubation with effector T
cells [5]. This method has long been considered to be poorly
quantitative and so was combined with the tedious and time
consuming process of limiting dilution in more rigorous studies [1].
Never-the-less comparisons of traditional cytotoxicity backed with
statistical analyses, for example to support the superiority of
vaccine candidates, remain commonly published. Cytotoxicity
assays that use fluorescent dyes and flow cytometry are now
becoming more common and also allow a variant of this assay to
be done in vivo. Using fluorescent dyes such as carboxyfluorescein
succinimidyl ester (CFSE), target cell populations loaded with
different antigenic peptides can be labeled with the dye at different
fluorescence intensities and the cytotoxic activity of CD8+ T cells
towards multiple target populations can then be assessed in the
same assay [6,7]. An advantage of this assay is that it measures
survival of targets rather than an indirect measure of cell death as
in the release of 51Cr. However these assays remain limited to
detecting the killing of targets, rather than the CD8+ T cells
themselves.
The use of tetrameric MHC/peptide complexes (tetramers)
revolutionized the field, allowing precise quantification of epitope-
specific CD8+ T cells and showing that these are far more frequent
(at least 10-fold) than suggested by the previous assays [8]. In
addition, other markers of activation, e.g. CD62L, CD44 and
granzyme B, can be analyzed in combination with tetramers.
However, tetramers and the various variants of this technology
alone do not demonstrate functional capability. There are two
main methods for detecting the production of cytokines after a
brief ex vivo stimulation: enzyme linked immunospot assay
(ELISpot) and intracellular staining with antibodies and flow
cytometric analysis (ICS) [9,10,11]. The most commonly detected
cytokine is IFNc for both assays. This choice is supported by
evidence that cytokine production by anti-viral CD8+ T cells is in a
hierarchy where IFNc is made by most cells, followed by a fraction
that also make TNFa and then others that make IL-2 as third
effector [12]. Therefore use of IFNc as a marker should detect the
greatest number of virus-specific CD8+ T cells with a simple
protocol for ELISpot or ICS. Here we focus on the ICS approach
and refer to the whole assay, including stimulation, as IFNc-ICS.
IFNc-ICS can be combined with detection of surface CD107a/b
to demonstrate degranulation, which is required for cytotoxic
function, during stimulation [13,14]. This allows at least one
aspect of each of the two major CD8+ T cell functions to be
combined with direct detection of CD8+ T cells. However, two
caveats remain: some populations of CD8+ T cells may respond by
making cytokines other than IFNc and the ability to degranulate is
only one of the requisites for cytotoxic ability [15]. More recently
an emphasis on polyfunctionality (the ability to make several
cytokines and exert cytotoxicity) has been introduced as it is clear
that CD8+ T cell quality is important, as well as quantity [16].
However, it remains important to quantify the denominator for
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any such studies and this will remain the total number of CD8+ T
cells capable of responding to a given viral specificity.
A central issue persists: how well do common assays that are
used to compare the size of CD8+ T cell responses stack up?
Anecdotal evidence and common opinion in the field seems to be
that IFNc-ICS fails to account for all anti-viral CD8+ T cells.
However direct comparisons of tetramers and IFNc production at
the single cell level have given conflicting results [17]. Use of
IFNc-based assays have been reported to detect fewer [18], more
[19], or similar numbers [20,21] of antigen-specific CD8+ T cells
than tetramers. Inclusion of degranulation as an extra marker has
not been examined and rigorous tests of the linear range of each
are also lacking. Simple staining with tetramers or similar reagents
followed by flow cytometry would be expected to give linear
results. However, where cells require activation by stimulation, as
in IFNc-ICS it is possible that the dynamics of culture might
introduce unexpected threshold effects.
In this study, we have addressed these issues using vaccinia virus
(VACV) and herpes simplex virus type 1 (HSV-1) infections of
mice and in vitro activated OT-I CD8+ T cells. In our first
approach we took advantage of recombinant viruses lacking a
dominant CD8+ T cell epitope and titrated splenocytes from mice
infected with a wild type virus into those from mice infected with
the epitope-deletion mutant. This allowed us to simulate real
samples with differing, but predictable levels CD8+ T cells of a
known specificity diluted by splenocytes from similarly infected
mice. The methods chosen for comparison were a) the DimerX
variant of tetramer technology [22,23], b) IFNc-ICS, c) IFNc-ICS
combined with CD107 mobilization (IFNc-ICS/CD107), and d) a
CFSE-based in vitro cytotoxicity assay. In a second approach, we
constructed different levels of epitope-specific CD8+ T cells in vivo
by activating OT-I cells in vitro and transferring known numbers of
these into mice. This enabled the inclusion of an in vivo cytotoxicity
assay in our comparisons.
Results
Reproducibility of IFNc-ICS
IFNc-ICS often shows substantial variance (shown by quite
large errors for some measurements) where CD8+ T cells are
enumerated using multiple mice as replicates [22,24,25]. We
wondered if this was a true reflection of the size of responses in
these mice or was generated by errors associated with the assay
itself. Therefore before attempting direct comparisons between
methods, we wanted to test the reproducibility of IFNc-ICS, one
method that relies both upon brief in vitro culture and antibody
staining for flow cytometric analysis. A group of three mice was
infected with VACV and seven days later, which is the peak of the
response, CD8+ T cell responses to five epitopes were measured by
IFNc-ICS, each epitope for each mouse being assayed in
quadruplicate (Figure 1). We were surprised by the reproducibility
of the IFNc-ICS assay, as shown by the very small error, and also
by the extent of differences between individual mice. Indeed, a one
way ANOVA comparing all three mice found statistically
significant differences across the mice for CD8+ T cell responses
to all epitopes and a post-test found differences for 13 of 15
possible pair-wise comparisons. We concluded that the IFNc-ICS
assay is highly reproducible and that substantial differences can
exist in responses of different mice to the same epitopes in the
same infection.
IFNc-ICS, DimerX and IFNc-ICS/CD107 are highly linear
and give comparable estimates of VACV-specific CD8+ T
cells
To directly compare numbers of CD8+ T cells detected and the
linearity of results produced by DimerX, IFNc-ICS and IFNc-
ICS/CD107 mobilization, splenocytes from VACV-infected mice
were serially diluted into splenocytes from VACV DB8R [26] -
infected mice. This created a series of samples in which B820-
specific CD8+ T cells are diluted in two-fold steps from their usual
level (around 6–8% of CD8+ T cells) to 64-fold less than this
amount. As a control, A3270-specific CD8
+ T cells were quantified
in parallel. In all assays, the CD8+ T cell response to B820 was
expected to decrease, while the response to A3270 should remain
the same because the total number of splenocytes in each well was
kept constant.
All methods gave similar results, but with DimerX consistently
giving the lowest estimate of the frequency of epitope-specific
CD8+ T cell responses and IFNc-ICS the highest (Figure 2A). This
was seen for B820, which varied across the dilution series as
expected, and for A3270, which stayed constant. However, the
difference between these methods was within the range that
responses were shown to vary between mice above. We then used
linear regression to analyze data from the titration of B820
responses to determine if each method accurately reflected the
expected dilutions (Figure 2B). For all three methods, the results
obtained demonstrated extremely high fidelity to the expected
result, with r2 values very close to one, the lowest being 0.9977 for
IFNc-ICS combined with CD107 mobilization. In a second
experiment, the three methods gave even more similar estimates of
the size of the B820-specific response (DimerX, 6.42%; IFNc-ICS,
6.75%; IFNc-ICS/CD107, 6.42%), being within the range of
replicates in the IFNc-ICS assay shown in Figure 1. Again r2
values for these methods were close to one (DimerX, 0.9771;
IFNc-ICS, 0.9910; IFNc-ICS/CD107, 0.9758).
Cytotoxicity assays reflect actual differences in CD8+ T
cell responses poorly
In vitro cytotoxicity assays were done using the same dilution
series of splenocytes as described above. The assay employed was
based on loss of fluorescently labeled target cells coated with
relevant peptides compared with those coated with an irrelevant
Figure 1. Reproducibility of IFNc-ICS. Three mice were infected i.p.
with VACV WR and after seven days CD8+ T cell responses to a set of
peptides (as shown on the figure) were measured by IFNc-ICS assays
done in quadruplicate for each peptide and each mouse. Backgrounds
determined using irrelevant peptides were subtracted from the values
presented. Data are mean 6 SEM. Reproducibility was similar in a
second experiment in which spleens were pooled from two infected
mice and responses to the set of peptides above assayed with 10
replicates.
doi:10.1371/journal.pone.0039533.g001
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peptide as detected by flow cytometry. The use of two dyes
allowed the simultaneous measurement of B820- and A3270-specific
killing in the same well. Further as is typical in cytotoxicity assays,
four E:T ratios were tested. As an overall impression, the level of
B820-specific killing did fall for each E:T ratio as the WR-immune
splenocytes were diluted with DB8-immune splenocytes, but this
was not true for each two-fold step (Figure 3A). Over the full 64-
fold dilution series, the drop in killing was approximately 3-fold,
suggesting that the cytotoxicity assay greatly underestimates
differences in actual responses. A3270-specific killing across the
same set of samples suggested similar killing across the samples, as
expected but again some individual wells gave irregular results. To
formalize the comparison of measured killing to actual CD8+ T
cell numbers for the B820-–specific response, regression analysis
was done for each E:T ratio (Figure 3B). The r2 values for the
various E:T ratios ranged from 0.6975 to 0.8184, all indicating
that the cytotoxicity assay fails to render differences in CD8+ T cell
responses in a linear fashion.
IFNc-ICS, DimerX and IFNc-ICS/CD107 are highly linear
and give comparable estimates of HSV-specific CD8+ T
cells
Next we wanted to extend our analyses to another acute virus
infection, to see if the equivalence of methods was a peculiar
feature of VACV infections. To do this we infected the flanks of
mice with HSV KOS and KOS K.L8A [27] and took spleens for
analysis seven days later. Splenocytes from HSV KOS infected
mice were diluted with splenocytes from KOS K.L8A infected
mice to make a similar set of dilutions as was done for VACV
(above). Reponses to the HSV epitopes HSV gB498 (expected to be
diluted across the series) and RR1982 (constant) were measured
using DimerX, IFNc-ICS and IFNc-ICS/CD107 methods
(Figure 4A). As was seen for the anti-VACV responses, all three
methods gave similar estimates of HSV-specific CD8+ T cell
responses. Further the linear fidelity of each of these methods was
also confirmed (Figure 4B). In contrast to the VACV experiment,
we noticed that the responses to the RR1982 epitope also changed
across the dilution series. The response to this peptide was lowest
in samples with splenocytes only from KOS-infected mice and
highest where they were all from KOS K.L8A-infected mice. This
was most likely due to immunodomination by gB498 in mice
infected with KOS and indeed the increase of response to RR1982
as KOS-immune splenocytes were diluted in K.L8A-immune
splenocytes was linear.
In vivo detection of antigen-specific CD8+ T cells by
DimerX assay, IFNc-ICS and a CFSE-based cytotoxicity
assay
The in vivo cytotoxicity assay is now very frequently used, so we
included this method in our comparison. This required a gradient
of CD8+ T cells of known specificity to be generated in a set of
mice. To do this we transferred two-fold dilutions of in vitro-
activated CD8+ OT-I T cells into a set of 5 mice. We used a
standard CFSE-based in vivo cytotoxicity assay, with targets being
allowed 4 hours for killing in the mice. The activation of OT-I in
vitro and the short assay time after transfer of targets eliminates the
complication of an endogenous response to SIINFEKL. When
spleens were taken to assess killing, we also used the splenocytes to
detect OVA257-specific CD8
+ T cells by IFNc-ICS and DimerX
staining. In the first experiment, we started with a maximum of
56106 CD8+ OT-I cells. As seen in other experiments DimerX
and IFNc-ICS again proved highly linear (r2 well above 0.95), with
these two assays giving similar results considering the whole
dilution series (Figure 5A and B). The in vivo cytotoxicity assay
appeared to have a plateau with less than 10% difference in killing
between the mice receiving the two highest doses of OT-I cells, but
in mice receiving between 2.56106 and 3.1256105 cells, the
Figure 2. Direct quantification of VACV-specific CD8+ T cells.
Splenocytes from mice infected with VACV-WR were serially diluted in
splenocytes from mice infected with VACV-DB8R-WR and CD8+ T cell
responses to the peptides B820 and A3270 were measured using three
methods. (A) Data from DimerX, IFNc-ICS and IFNc-ICS/CD107 methods
as indicated on each graph. Backgrounds determined using irrelevant
peptides were subtracted from the values presented. (B) Linear
regression analysis and r2 statistics for quantification of B820–specific
CD8+ T cells by each method. Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0039533.g002
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cytotoxicity showed relatively good linear fidelity (r2 = 0.9965). To
test this apparent plateau, followed by a range of linear response, a
second experiment was done, this time starting with 16107 CD8+
OT-I cells (Figure 5C and D). Here only IFNc-ICS was used for
comparison and again this assay was highly linear. In contrast, we
confirmed the plateau in killing for high numbers of CD8+ OT-I
cells, but in this experiment only one step (2.56106 to 1.256106
OT-I) approximated the expected two-fold difference and the
overall r2 was lower for this than the first experiment (r2 = 0.7670).
Suggesting that the linear range we saw in the first experiment is
not a consistent feature of in vivo cytotoxicity assays.
Figure 3. Measuring in vitro cytotoxicity of VACV-specific CD8+
T cells. The same set of serial dilutions of splenocytes from VACV WR
and VACV DB8R mice as made for the experiments in figure 2 were used
as a source of effectors in an in vitro cytotoxicity assay. Target cells were
RMA cells coated with B820 or A3270 and these were incubated with
effectors at the E:T ratios shown. (A) The percent loss of B820 or A3270
(as shown on graphs) coated cells as compared with non-peptide-
coated control targets. (B) Linear regression analysis and r2 statistics
derived from the B820–specific killing data shown in panel A. Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0039533.g003
Figure 4. Direct quantification of HSV-specific CD8+ T cells.
Splenocytes from mice infected with HSV KOS were serially diluted in
splenocytes from mice infected with HSV K.L8A and CD8+ T cell
responses to the peptides gB498 and RR1982 were measured using three
methods. (A) Data from DimerX, IFNc-ICS and IFNc-ICS/CD107 methods
as indicated on each graph. Backgrounds determined using irrelevant
peptides were subtracted from the values presented. (B) Linear
regression analysis and r2 statistics for quantification of gB498–specific
CD8+ T cells by each method.
doi:10.1371/journal.pone.0039533.g004
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Discussion
Here we present a rigorous comparison of the linear fidelity of
several frequently used methods for enumerating anti-viral or
vaccine-specific CD8+ T cells. The main motivation was our
frequent experience of statements about the limitations of various
methods being made, but rarely backed by evidence beyond
anecdote. The following comments are restricted to the situations
that we studied here, namely acute viral infection in immuno-
competent mice.
In our first experiment, we were surprised at the reproducibility
of the IFNc-ICS assay, expecting that in other cases where assays
for each mouse were done once, variance would be roughly
equally derived from real differences between mice and errors
associated with the assay. In practice the majority of variance is
accounted for by mouse-to-mouse variation. As an additional
observation of interest, where responses to the dominant B820
were highest (mouse 2), responses to the less dominant epitopes
were reduced. This suggests that immunodomination does play a
demonstrable, if small role in setting the peak responses to epitopes
in this model, contrary to a recent report [28].
We show clearly here that in anti-VACV and -HSV responses
there are very few if any DimerX+ CD8+ T cells that fail to express
an anti-viral function in vitro and that similar numbers of CD8+ T
cells respond to peptide by making IFNc alone, as make IFNc and
degranulate. This is based on results across multiple experiments
and for levels of epitope-specific CD8+ T cells spanning nearly two
orders of magnitude, which is the typical range seen in most
publications. However, some considerations apply to these results.
First, the use of DimerX allows a highly similar negative control
reagent to be used because these reagents are loaded with a test, or
irrelevant peptide and dimerized with the secondary antibody
immediately prior to each experiment. Without subtracting values
from this negative control DimerX reagent, the results from the
tetramers would be higher and a discrepancy between this and the
functional methods would be found. With the original tetramer
technology, the quality of each reagent can differ between batches
of monomer as can the efficiency of tetramerization, which is also
done on a batch basis. This means that there is a unique non-
specific background associated with each batch of any tetramer
that cannot be accurately controlled unless a virus or vaccine
lacking the antigen of interest is used and this is rarely practical.
Inability to account for background may inflate estimations of
epitope-specific CD8+ T cells using these reagents. Second, we
were careful to use well verified CD8+ T cell epitopes for these
Figure 5. Comparison of DimerX, IFNc-ICS and an in vivo cytotoxicity assay. OVA257-specific CD8
+ T cells were generated from OT-I mice
and increasing numbers were injected i.v. into B6 mice. After 24 hours, naı¨ve B6.SJL splenocytes coated with OVA257 (labeled CFSE
high) mixed with
uncoated splenocytes (labeled CFSElow) were injected i.v. into the OT-I T cell-treated B6 mice. After 4 hours, splenocytes were prepared and the
percentage of OVA257-specific CD8
+ T cells was determined by DimerX and/or IFNc-ICS and OVA257–specific killing measured by comparing recovery
of CD45.1+ CFSEhigh and CFSElow cells. Two experiments are shown (A and C) and graphs are labeled with the method used. (B and D) Linear
regression analysis and r2 statistics for the experiments shown in panels A and C, respectively.
doi:10.1371/journal.pone.0039533.g005
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studies. Where poorly mapped peptides are used, even at the high
concentrations typically used for IFNc-ICS assays, they may fail to
trigger all possible responses by all clones of CD8+ T cells that are
generated by the bona fide epitope in vivo. This is because the ability
to express various functions is related to antigen density [29,30]
and if this threshold is artificially high owing to an incorrectly
mapped peptide being used, this may result in apparent functional
differences in the responding CD8+ T cells. Third, related to the
last point, the elicitation of any anti-viral function ex vivo triggered
by unphysiologically high amounts of peptide cannot be taken to
infer that this response occurs in vivo. Results gained with IFNc-
ICS or ELISpot assays are often referred to as the ‘IFNc-
response’, but the expression of this cytokine in the anti-viral
response will depend on the functional avidity of the CD8+ T cells
and the level of epitope that is presented on virus infected cells in
vivo [12]. The latter parameter is at present not known for any
epitope from any virus. This together with our data shown here
suggest that IFNc-ICS as used with typically high peptide
concentrations (161027 M or greater) is a more appropriate
method for counting all antigen-specific CD8+ T cells than for
inferring any functional capacity. Until the amounts of any peptide
presented on infected cells in vivo are known, even diluting peptides
to levels that are closer to the physiological range does not give
certainty that the measured function will be manifest in fighting
infection. Finally, it cannot be assumed from the above that IFNc-
ICS and DimerX or tetramer staining will always give equivalent
results. Examples might include knock-out or mutant mice with
defects in aspects of T cell function, the study of pathogens that
adversely affect immune function or that dramatically skew
responses away from a typical Th1 profile. In addition, we have
not tested memory CD8+ T cells. However, our data from
experiments where OT-I cells were activated in vitro and
transferred into mice suggest that the data is very likely to be
generalizable beyond the VACV and HSV models. So we
conclude that these results will hold for the majority of acute
anti-viral responses and perhaps other intracellular pathogens.
In contrast to the methods discussed above, both assays of
cytotoxicity failed to accurately reflect differences in CD8+ T cell
numbers. The main deficiency of the in vitro assay was that while
results roughly correlated with number of effectors, they led to a
gross underestimation of differences, with the 64-fold range of
CD8+ T cell numbers being compressed to less than four-fold
difference in cytotoxicity. However, the regularity of the decline of
lysis with cell number suggests that if a standard curve could be
constructed (as we have done), then a rough estimation of the real
difference in response underlying any difference in lysis could be
made. This is not possible in most cases so applications of this
method used to make quantitative statements should be interpret-
ed with great caution. The in vivo assay likewise failed to reflect real
differences in CD8+ T cells, but in this case a plateau effect was
seen for higher numbers of antigen-specific CD8+ T cells. It is
important to add that the experiment was constructed to assay
numbers of OT-I CD8+ T cells across a range that typically occurs
in anti-viral CD8+ T cell responses, so this plateau would be
experienced in real-world applications. We used a relatively short
assay time (four hours) for the in vivo cytotoxicity assay and so
where longer times are used, it is likely that the plateau would
extend to lower numbers of cytotoxic CD8+ T cells. Conversely,
shortening the time of the assay might allow better dissection of
responses where frequency of effectors is high. It is possible that
the time required to achieve a particular level of lysis might be a
better correlate of the frequency of effectors, but this would be a
very impractical assay and so was not tested here. Our in vivo
cytotoxicity assay only examined killing of targets in the spleen. At
very early times (two days after infection) killing is confined to a
single lymph node [31], which implies that it occurs in secondary
lymphoid tissue, but by the peak of the CD8+ T cell responses it is
seen across lymph nodes and spleen and so is probably systemic
[31,32,33]. This suggests that the spleen is good as a representative
organ for measuring cytotoxicity. However, killing is also reflected
in some non-lymphoid tissues (lung, liver) [32,33] and it remains
possible that the results at these sites might differ from spleen.
Finally, both these assays of cytotoxicity rely on targets coated with
unphysiologically high levels of peptide and so they are unable to
provide certainty that the lysis measured would translate to killing
of infected cells in a real anti-viral response.
In conclusion, we show strong data here to support the
reproducibility and linear fidelity of IFNc-ICS alone or combined
with CD107 as a marker for degranulation as well as its similarity
to DimerX staining in acute anti-viral CD8+ T cell responses. By
contrast, assays of cytotoxicity in vitro or in vivo fail to accurately
reflect differences in CD8+ T cell responses. These data are helpful
to interpret the wealth of published comparisons of CD8+ T cell
immunogenicity, especially in the field of vaccinology where
accurate pre-clinical assessment of different candidates is crucial.
Materials and Methods
Viruses and cell lines
VACV strain Western Reserve (VACV WR, ATCC#VR1354)
was grown and titrated in cells respectively using standard
methods. VACV strain WR was a gift of Bernard Moss (NIH,
Bethesda). VACV DB8R was a gift from Geoffrey L Smith
(University of Cambridge) and has been shown to have equal
virulence in mice compared with parental strain, VACV WR [26].
HSV-1 strain KOS and KOS variant K.L8A, which lacks the
anchor residue of the dominant gB498–505 peptide, but has wild
type virulence [27], were a gift from Francis Carbone. All viruses
were grown and titrated by standard methods using BHK-21 and
BS-C-1 respectively for VACV and Vero cells for HSV-1.
Immortalized cell lines BHK-21, BS-C-1 and RMA were
maintained in Dulbecco’s Modified Eagle medium (DMEM,
Invitrogen) with 2 mM L-glutamine and 10% fetal bovine serum
(FBS) (D10). Vero cells were grown in Minimal Essential Medium
supplemented with 10% FBS, 2 mM L-glutamine, 5 mM HEPES
and 50 mM 2-mercaptoethanol (all Invitrogen).
Synthetic peptides
Lyophilized peptides were purchased from Genscript Corp.
(Piscataway, NJ) or Mimotopes (Clayton, Vic Australia). Master
stocks of peptides were made at 10 mg/ml in 100% dimethylsulf-
oxide (DMSO) and stored at 270uC. Before use, peptides were
diluted to the required concentrations in serum-free DMEM with
L-glutamine (D0). Peptide sequences used were: VACV B820-27,
TSYKFESV [34]; VACV A3270–277, KSYNYMLL [35]; VACV
K36–15, YSLPNAGDVI [34]; VACV A47138–146, AAFEFINSL
[34]; VACV B6108–116, LMYDIINSV [35]; HSV gB498–505,
SSIEFARL [36]; HSV RR1982–989, FAPLFTNL [37]; chicken
ovalbumin257–264 SIINFEKL [38].
5(6)-Carboxyfluorescein-diacetate N-succinimidyl (CFSE)
CFSE was purchased from Sigma-Aldrich. A stock solution was
made at 1 mg/ml in DMSO and aliquots were stored at 220uC.
Before use, stocks were diluted to required concentrations in D0.
Ethics Statement
All experiments were done according to Australian NHMRC
guidelines contained within the Australian Code of Practice for the
Quantifying Anti-Viral CD8+ T Cells
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Care and Use of Animals for Scientific Purposes and under
approvals F-BMB-38.8 and A2011-01 from the Australian
National University Animal Ethics and Experimentation Com-
mittee.
Mice and infections
Specific pathogen-free female C57BL/6 mice, C57BL/6.SJL
mice and OT-I transgenic [39] mice greater than 8 weeks of age
were obtained from Animal Resource Centre (Perth, Australia) or
the ANU Bioscience Resource Facility. Mice were infected
intraperitoneally (i.p.) with 16106 plaque forming units (PFU) of
VACV in 200 ml PBS. Alternatively mice had left flanks shaved
and depilated (Veet cream for sensitive skin, Reckitt Benckiser)
before being infected with HSV-1 by tattoo, using a 10RS needle
cluster dipped in virus at 16108 PFU/ml and applied for
10 seconds. This method for HSV inoculation results in similar
pathogenesis compared with infection by scarification as originally
described [40].
DimerX reagent and monoclonal antibodies (mAbs)
Recombinant soluble dimeric mouse H-2Kb:Ig fusion protein
and anti-mouse IgG1 (clone A85-1) conjugated with phycoerythrin
(PE) were purchased from BD Biosciences. Anti-mouse CD8a
(clone 53–6.7) conjugated with PE or allophycocyanin (APC), anti-
mouse IFNc (clone XMG.2) conjugated with APC, anti-mouse
CD107a (LAMP-1; clone 1D4B) and anti-mouse CD107b (Mac-3;
clone M3/84) labeled with fluorescein isothiocyanate (FITC) and
anti-mouse CD16/CD32 (Fc-block) (clone 2.4G2) were obtained
from BD Biosciences or BioLegend.
Preparation of and serial dilution splenocytes
Splenocytes were prepared from VACV-WR- and VACV-
DB8R-infected mice and adjusted to 16107 cells/ml. To make a
series of samples where B820-specific CD8
+ T cells are diluted,
splenocytes from VACV-WR-infected mice were mixed with
splenocytes from VACV-DB8R-WR-infected mice in a series of
steps to achieve the range of 100% to 1.5625%. The same method
was used to dilute splenocytes from HSV-1 KOS-infected mice
into those from and K.L8A-infected mice. For DimerX, IFNc-ICS
and IFNc-ICS/CD107 assays, 100 ml of mixed splenocytes were
used per well.
Detection of peptide-specific CD8+ T cells using DimerX
reagents
DimerX staining was performed according to the manufactur-
er’s instructions. Briefly, 2 mg of H-2Kb:Ig fusion protein was
incubated overnight at 37uC in PBS with a 40 M excess of a test or
irrelevant peptide. Peptide-loaded dimers were then incubated for
1 h at room temperature with PE-conjugated anti-mouse IgG1
(clone A85-1). Binding the bivalent secondary antibody turns the
DimerX reagents into dimers and as each of these displays two
peptide MHC surfaces, the final staining reagent is effectively a
peptide-MHC tetramer. Splenocytes (16106 per sample) were
labeled with peptide-loaded dimers and 1/200 anti-CD8-APC for
1 h on ice and washed twice before acquisition on a FACS LSR II
(BD Biosciences). Analysis was done using Flowjo software (Tree
Star Inc.). Events were gated for live lymphocytes on FSC6SSC
followed by CD8+ T cells 6 DimerX+ cells. Backgrounds
determined by using dimers loaded with irrelevant peptide were
subtracted from the values presented for test samples and were
generally in the order of 0.5%.
IFNc ICS
Splenocytes (100 ml of a 16107 per ml suspension in D10) were
plated in wells of round-bottom 96-well plates. Peptides were
added to a final concentration of 1027 M and plates were
incubated at 37uC and 5% CO2. After 1 h, 5 mg/ml brefeldin A
(Sigma) was added, and plates were incubated for another 3 h.
Plates were spun at 4uC, medium was removed, and cells were
resuspended in 50 ml of 1/150 diluted anti-CD8-PE. After 30 min
incubation on ice, cells were washed, resuspended in 50 ml of 1%
paraformaldehyde, and incubated at room temperature for 20 min
before another two washes and staining with 50 ml of 1/200
diluted anti-IFNc-APC in PBS with 2% FBS and 0.5% saponin
(Sigma) at 4uC overnight. Cells were washed three times before
acquisition using a FACS LSR II. Analysis was done using Flowjo
software. Events were gated for live lymphocytes on FSC6 SSC
followed by CD86IFNc. Data was recorded as IFNc+ events as a
percentage of total CD8+ events. Backgrounds as determined using
irrelevant peptides were usually in the order of 0.1% or less and
were subtracted from the values presented for test samples.
Simultaneous staining of cell surface CD107a/b and IFNc-
ICS
Splenocytes (100 ml of a 16107 per ml suspension in D10) were
plated in wells of round-bottom 96-well plates. Fc-block, peptides
(1027 M), Golgi-Stop (BD Biosciences) and a 1:1 mixture of anti-
CD107a/b-FITC was added. Plates were incubated at 37uC and
5% CO2 for 4 h. Plates were spun at 4uC, medium was removed,
and cells were resuspended in 50 ml of 1/150 diluted anti-CD8-
PE. After 30 min incubation on ice, cells were washed,
resuspended in 50 ml of 1% paraformaldehyde, and incubated at
room temperature for 20 min before another two washes and
staining with 50 ml of 1/200 diluted anti-IFNc-APC in PBS with
2% FBS and 0.5% saponin overnight at 4uC. Cells were washed
three times before acquisition using a FACS LSR II. Analysis was
done using Flowjo software. Events were gated for live lympho-
cytes on FSC6SSC followed by CD8+ T cells using CD86SSC
and displayed as CD107a/b+ 6 IFNc+. Data was recorded as
CD107a/b+, IFNc+ cells as a percentage of total CD8+ cells.
Backgrounds as determined using irrelevant peptides were usually
in the order of 0.1% or less and were subtracted from the values
presented for test samples.
In vitro cytotoxicity assay
Splenocytes from virus infected mice or uninfected control mice
were used as effectors and peptide-loaded, CFSE-labeled RMA
cells were used as targets. RMA cells (16106/ml in D0) were
incubated with a 1/600 dilution of Vybrant DiD cell labeling
solution (Molecular Probes) for 1 hour at 37uC, washed and split
into three populations. One population was loaded with 1027 M
B820 peptide for 1 hour at 37uC and labeled with a high
concentration (2.5 mM) of CFSE for 8 min at 37uC (CFSEhigh
cells). The second population was pulsed with 1027 M A3270
peptide and labeled with a low concentration (0.25 mM) of CFSE
(CFSElow cells). The third population was pulsed with 1027 M of
an irrelevant peptide and was left unlabelled. CFSE labeling was
stopped by addition of cold D10. Cells were washed with PBS,
mixed together in equal proportions and adjusted to 16105/ml
D10. 100 ml (16104) of target cells were plated into V-bottom 96-
well plates and co-incubated with effector splenocyte populations
at effector: target (E:T) ratios of 100, 50, 20 and 10 for 16 hours at
37uC with 5% CO2. Cells were washed in PBS with 2% FBS and
fixed in 1% paraformaldehyde before acquisition using a FACS
LSR II. Analysis was done using Flowjo software. Cells were gated
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for live RMA cells on the FSC6SSC, followed by gating on DiD+
cells. DiD+ cells were further gated on CFSEhigh, CFSElow and
CFSEneg cells. To calculate specific lysis, the following formula was
used: ratio = (percentage CFSEneg/percentage CFSEhigh) for B820
or ratio = (percentage CFSEneg/percentage CFSElow) for A3270.
Percent specific lysis = [1– (ratio naı¨ve effectors/ratio immune
effectors)6100].
Activation and transfer of OT-I cells and in vivo
cytotoxicity assay
Splenocytes were prepared from OT-I mice and half of them
were pulsed with 1027 M OVA257 peptide for 1 hour at 37uC. To
activate OT-1 specific CD8+ T cells, equal numbers of pulsed and
unpulsed splenocytes were co-cultured for 4 days in D10
containing 561025 M 2-mercaptoethanol and 1.25 ng/ml rIL-2
(R&D Systems). The cultures were diluted 1/2 on days 2 and 3
with fresh medium containing rIL-2. On day 4, cells were
harvested and transferred into B6 mice via intravenous (i.v.)
injections in a total volume of 200 ml PBS. To prepare target cells
for a CFSE-based cytotoxicity assay, naı¨ve B6.SJL splenocytes
(CD45.1+) were pulsed with 10–7 M OVA257 peptide for 1 hour at
37uC and labeled with a high concentration (2.5 mM) of CFSE for
8 min at 37uC (CFSEhigh cells). Unpulsed B6.SJL splenocytes were
labeled with a low concentration (0.25 mM) of CFSE (CFSElow
cells). CFSE labeling was stopped by addition of cold D10. Cells
were washed with PBS and mixed together in equal proportions.
1–26107 mixed cells were injected i.v. into B6 mice that had been
injected with OVA257-specific CD8
+ T cells 24 hours earlier.
Naı¨ve mice were used as controls. Mice were sacrificed 4 hours
later and spleens were harvested. CD45.1+ CFSEhigh/low cells were
measured to determine in vivo cytotoxicity. Percentage of lysis was
calculated as follows: [1– (ratio naı¨ve mouse/ratio test mouse)]
6100 where the ratio in each mouse is percentage CFSElow/
percentage CFSEhigh.
Statistics
A one way ANOVA was used for comparisons where there were
more than two groups, with pair-wise comparisons within these
data sets being done using a Bonferroni’s multiple comparison post
test (GraphPad Prism). Best fit linear regression and r2 statistics
(coefficient of determination) were calculated using GraphPad
Prism.
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